NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
03:43pm, Tuesday, 19'th Apr 2022
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
01:15am, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates
09:55pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
09:55pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
12:00pm, Sunday, 27'th Mar 2022 The Motley Fool
Another player has stuffed its pipeline with many coronavirus candidates.
Which Company Has the Biggest COVID Program? The Answer Isn't Moderna.
08:00am, Sunday, 27'th Mar 2022
Another player has stuffed its pipeline with many coronavirus candidates.
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
01:00pm, Friday, 25'th Mar 2022 GlobeNewswire Inc.
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial b
10 Biggest Price Target Changes For Friday
11:48am, Friday, 25'th Mar 2022 Benzinga
Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.
RBC Capital lowered Axalta Coating Systems Ltd. (NASDA
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
12:55pm, Thursday, 24'th Mar 2022 Zacks Investment Research
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sorrento's Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants
10:20am, Monday, 21'st Mar 2022
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced the publication of a preprint entitled "Chimeric mRNA based COVID-19 vaccine induces protective immunity against Omicron and Delta." Serum collect
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Potent Neutralizing Antibodies and Protection Against Omicron (BA.1 and BA.2) and Delta Variants
09:26pm, Sunday, 20'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 20, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat can
Why Sorrento Therapeutics Stock Bumped Higher Today
09:30pm, Friday, 18'th Mar 2022 The Motley Fool
A majority-owned subsidiary reports very good clinical trial results for a leading pipeline drug.
Why Sorrento Therapeutics Stock Bumped Higher Today
05:30pm, Friday, 18'th Mar 2022
A majority-owned subsidiary reports very good clinical trial results for a leading pipeline drug.
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I
07:35pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
NEW YORK and PALO ALTO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a
